The Bharat BioTech’s Phase -1 trials shown promising results vaccine was well tolerated in all groups. The COVAXIN is India’s first indigenous vaccine. The phase-1 trials was conducted on 375 volunteers. “The vaccine was well tolerated in all dose groups with no vaccine-related serious adverse events. Interim findings from phase 1 trial of Covaxin: After 1st vaccination, local & systemic adverse events were predominantly mild/moderate in severity & resolved rapidly, without prescribed medication. The most common adverse event was pain at the injection site which resolved spontaneously.” Bharat BioTech said in a research papers
The company has said the majority of mild symptoms have been observed during the study but no major serious adverse effect have been reported.
“Only one serious adverse event was reported that was unrelated to the vaccination,” the company said in the research papers published on https://www.medrxiv.org/content/10.1101/2020.12.11.20210419v1.full.pdf
In recent years, India has made significant strides in the fight against cancer, with an…
As we age, our cognitive abilities naturally decline, but diet has emerged as a key…
In a significant move toward revolutionizing patient care, a panel discussion on Artificial Intelligence (AI)-based…
Breast cancer remains one of the leading causes of cancer-related deaths among women worldwide. Early…
Airport Proximity: Can living near an airport increase your risk of a heart attack? A…
Antimicrobial resistance (AMR), the ability of bacteria, fungi, and parasites to resist the effects of…